1. Home
  2. MG vs TSHA Comparison

MG vs TSHA Comparison

Compare MG & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MG
  • TSHA
  • Stock Information
  • Founded
  • MG 1978
  • TSHA 2019
  • Country
  • MG United States
  • TSHA United States
  • Employees
  • MG N/A
  • TSHA N/A
  • Industry
  • MG Military/Government/Technical
  • TSHA Biotechnology: Pharmaceutical Preparations
  • Sector
  • MG Consumer Discretionary
  • TSHA Health Care
  • Exchange
  • MG Nasdaq
  • TSHA Nasdaq
  • Market Cap
  • MG N/A
  • TSHA 397.8M
  • IPO Year
  • MG 2009
  • TSHA 2020
  • Fundamental
  • Price
  • MG $7.79
  • TSHA $2.10
  • Analyst Decision
  • MG
  • TSHA Strong Buy
  • Analyst Count
  • MG 0
  • TSHA 8
  • Target Price
  • MG N/A
  • TSHA $6.63
  • AVG Volume (30 Days)
  • MG 116.6K
  • TSHA 2.9M
  • Earning Date
  • MG 05-07-2025
  • TSHA 05-16-2025
  • Dividend Yield
  • MG N/A
  • TSHA N/A
  • EPS Growth
  • MG N/A
  • TSHA N/A
  • EPS
  • MG 0.47
  • TSHA N/A
  • Revenue
  • MG $706,813,000.00
  • TSHA $8,333,000.00
  • Revenue This Year
  • MG $5.76
  • TSHA N/A
  • Revenue Next Year
  • MG $2.88
  • TSHA N/A
  • P/E Ratio
  • MG $16.52
  • TSHA N/A
  • Revenue Growth
  • MG N/A
  • TSHA N/A
  • 52 Week Low
  • MG $7.06
  • TSHA $1.05
  • 52 Week High
  • MG $12.44
  • TSHA $4.32
  • Technical
  • Relative Strength Index (RSI)
  • MG 27.60
  • TSHA 58.01
  • Support Level
  • MG $8.87
  • TSHA $1.85
  • Resistance Level
  • MG $9.70
  • TSHA $2.73
  • Average True Range (ATR)
  • MG 0.40
  • TSHA 0.27
  • MACD
  • MG -0.04
  • TSHA 0.04
  • Stochastic Oscillator
  • MG 27.65
  • TSHA 58.47

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Share on Social Networks: